Moneycontrol PRO
you are here: HomeNewsWorld

Sanofi says COVID-19 vaccine candidate yields positive trial data

"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK, said in a statement.

June 24, 2022 / 11:19 AM IST
Source: Reuters

Source: Reuters

Sanofi's COVID-19 vaccine candidate, which is modelled on the virus's Beta antigen, delivered 72% efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study.

"Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK, said in a statement.

The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.
Reuters
first published: Jun 24, 2022 11:19 am
Sections
ISO 27001 - BSI Assurance Mark